Boehringer-Ingelheim has renewed its collaboration with VTU technology to develop a yeast-based protein expression system for biopharmaceutical production.
Horizon says its £6m (€7.7m) purchase of Austrian biotech Haplogen Genomics means it can produce cell lines ten times faster than before using a haploid gene platform.
Richard the III was blond, blue-eyed and may owe a substantial parking fine based on new genetic research that solves a 529-year old missing persons case.
There is an upsurge in biopharma demand for cell and gene therapy applications, says Transposagen as it inks a deal with Janssen to develop allogeneic Chimeric Antigen Receptor (CAR) T-cells.
Isis Pharmaceuticals and AstraZeneca have expanded their partnership to develop novel delivery methods for antisense oligonucleotides in order to target the desired tissue more effectively.
CRISPR, the gene-editing technology that could revolutionise biologics, is set to become a patent battleground as companies vie over who owns the tool and its products, says an intellectual property expert.
Baxter International will spin off its biopharmaceutical treatments and manufacturing facilities to form a new company known as Baxalta, which is expected to launch in mid-2015.
Protalix shares rocketed 18% then reversed in one weekend after the Israeli protein manufacturer clarified it is not in talks to produce Ebola drug ZMapp.
AMRI has added protein expression and purification services to its drug discovery services citing the shift in pipelines towards larger molecule drugs as a driver.
CRISPR gene editing will make cell line development cheaper and faster according to Horizon Discovery, which says that new tech has application in both biomanufacturing and preclinical disease modelling.
Miltenyi Biotec has acquired the lentiviral vector manufacturing business and related assets from Lentigen, a lentiviral technology provider for cell and gene therapy applications.
Though mostly known for its work in measurements, the National Institute of Standards and Technology’s work is expanding in biomanufacturing and specifically looking to standardize the identification of CHO (Chinese hamster ovary) and rat cell lines as...
The complex nature of biopharmaceuticals dictates the choice of contract manufacturer when compared with selecting a partner for small molecule drugs, according to a life sciences consultant.
The European Medicines Agency’s Committee for Advanced Therapies (CAT) has revised a reflection paper on the classification of advanced-therapy medicinal products (ATMPs) to reflect cases in which medicines can be classified as ATMPs.
Thermo Fisher Scientific has licensed rights to gene editing technology for bioproduction applications that it claims targets DNA more precisely and reliably than current approaches.
French mAb developers that hire Cobra Biologics stand to benefit from tax breaks after the French Ministry of Higher Education and Research (MESR) named the CMO as a preferred provider.
Cobra Biologics is looking for more scientists with plasmid production skills after BioCancell became the fifth firm in a year to ask the CMO to manufacture a DNA-based gene therapy candidate.
Transposagen says its XTN Talen technology is more flexible than Zinc Finger Nuclease (ZFN) platforms for gene editing and creating genetically engineered cell lines.
Thermo Fisher Scientific completed its takeover of Life Technologies last night, just two days after the US Federal Trade Commission (FTC) approved the $13.6bn deal.
Sanofi and French biopharma Transgene will soon begin construction on their new €10m ($13.5m) manufacturing plant, which will produce viral vectors for Transgene's targeted cancer immunotherapy, TG4010.
The European Commission (EC) has cleared Thermo Fisher’s acquisition of Life Technologies subject to certain divestitures including its media and sera for cell culture business.
Horizon Discovery has licensed a zinc finger nuclease (ZFN) technology from Sigma-Aldrich and says the combination with its own platform will be “a big step forward in gene editing.”
Bioreliance has launched an updated version of its mutagenicity service after conducting studies that confirmed its Big Blue Mouse assay still meets OECD standards.
Mitsubishi Tanabe Pharma (MTPC) is closer to adding two plant-based expression techs to its manufacturing arsenal after Medicago shareholders back its takeover bid.
A new genetically modified strain of E. Coli cells could create enough protein for downstream production without the need for the challenging endotoxin removal steps that are currently employed.
With the Chinese NAP (nucleic acid purification) market expected to grow more than 8% over the next year and no clear market leaders, companies are looking to take control of the industry space.
As Cobra wins a cell line development contract with Recopharma, the firm says its cost-effective gene expression technology has been its biggest growth area.
Food industry controls do not ensure porcine trypsin is virus-free according to the EMA, which proposes testing procedures for drugmakers which use the reagent in a new consultation document.
Thermo Fisher Scientific has set up a unit for molecular biology techs at its site in Lithuania, citing pharmaceutical R&D labs in Eastern Europe as a target.
Cell Biosciences plans to gain ground in the protein-based drugs market by acquiring Convergent Bioscience at the end of October for a cash sum of $12m (€8.6m.)
